For decades, the clozapine REMS program was one of the most well-known safety initiatives done by the FDA. The program was designed to reduce the risk of severe neutropenia. This REMS program has also been a popular target for board exam questions. But is the...
Insulin icodec may have a new competitor in the near future. Insulin efsitora is another once-weekly insulin currently undergoing phase 3 clinical trials, with Lilly’s 3rd phase being termed the QWINT trials (Once Weekly (QW) Insulin Therapy (INT)). These trials are...
Fezolinetant (Veozah) is a central nervous system agent that works as an antagonist at the neurokinin 3 (NK3) receptor. This action inhibits neurokinin B (NKB) binding on the kisspeptin/neurokinin B/dynorphin (KNDy) neuron which alters activity in the thermoregulatory...
The FDA has been busy this year reviewing new medications. As a practicing pharmacist, it is hard to remember everything so I wanted to outline the top 5 drug approvals in 2024 that may impact ambulatory care and geriatrics. Without further ado, here’s my top 5...
Neffy is the brand name for intranasal epinephrine that can be used for type I allergic reactions such as anaphylaxis. In this article, we will highlight some of the differences and similarities between Neffy and Epipen. Neffy was approved for patients who weigh over...
I’ve encountered a significant proportion of patients who are on chronic benzodiazepines. Drug interactions, adverse effects, and other risks to my geriatric patient population are significant when using this class of medication. Benzodiazepine withdrawal is...
